Regulatory T cells (Treg) are crucial in the proper balance of the immune system. A better characterization of Treg-specific genes should extend our knowledge on their complex biology. However, to date there is no consensual Treg signature in the literature. Here, we extracted a molecular Treg meta-signature relative to CD4 + conventional T cell from 8 different but comparable publicly available microarray datasets. We confirmed the validity of our result using the much larger but less stringent Immuno-Navigator database. However, many genes of the Treg meta-signature were also expressed at the protein level by other immune cell subsets, as assessed by mass cytometry, with the noticeable exceptions of Il2ra, Ctla4, and 
Introduction
Proper number and function of regulatory T cells (Treg) are essential for a wellbalanced immune system: too few of these cells leads to autoimmunity and too much prevents an efficient immune response, with harmful consequences for anti-tumor immunity, for instance. Treg are a subset of CD4 + T cells that express the transcription factor (TF) Foxp3 and the alpha chain of the interleukin-2 receptor CD25, both indispensable for suppressive functions and proper homeostasis. Probably the best example illustrating the crucial role for Foxp3-expressing cells in the homeostasis of the immune system is given by the lethal auto immune syndrome seen in patients bearing mutations in the FOXP3 gene, the IPEX syndrome (1) . Like most CD4 + T cells, Treg are generated in the thymus upon MHC-driven selection based on affinity of the T cell receptor for self antigens (2) . A sizable proportion of those cells are also induced in the periphery (pTreg) from CD4+ T cells precursors, but those pTreg are reported not to express Helios or Neuropilin-1, contrary to thymic-derived Treg (tTreg) that are positive for those markers (3) . Known pTreg inducers in the periphery can be byproducts of bacterial metabolism (4, 5) but it is likely that inflammation per se is a main driver for pTreg differentiation (6) . Thus, finding ways of manipulating Treg for therapeutic purposes in the auto immunity field has become a major endeavor for immunologists worldwide. Moreover, recent results linking the presence of Treg to a bad prognostic in some cancers extended their potential clinical applications from autoimmunity to cancer immunotherapy (7) . In the case of cancer, one would want to get rid of Treg to wake up a dim immune response to tumors. An example of this powerful approach has been recently illustrated by Treg-depleting CTLA-4 or CD25-specific mAb (8, 9) . However, this weak response to tumors is part of a natural tolerance process, preventing the immune system to attack self-tissues. Thus, breaking immune tolerance by removing Treg is not without consequences on the integrity of healthy tissues. This is illustrated by studies showing that Ipilimumab (anti-CTLA-4), a powerful anti-cancer drug affecting Treg, indeed help the immune system to fight tumors at the expense of a generalized auto immunity in treated patients (10) .
A better knowledge of Treg biology will be crucial for preserving therapeutic efficacy without severe adverse events. This knowledge has been mostly collected from mice due to their ease of use, their versatility and the thousands of genetic models available to answer mechanistic questions.
To that end, hundreds of investigators have pursued the quest for specific Treg markers, revealing molecules and pathways that can be targeted by monoclonal antibodies or pharmacological compounds. However, there are still confusions about these specific markers, since the comparisons are often made across unrelated studies employing different technologies. Moreover, a characteristic of Treg is their ability to adapt to the cellular environment in which they are present. This mechanism, referred as to effector class control few years ago (11) , deeply affect cell surface phenotype and thus presumably, gene expression patterns. In addition, there are evidences that pTreg, contrary to tTreg, might be relatively unstable (12) , meaning that pTreg may acquire some pro-inflammatory effector functions. Furthermore, it appears that tissue Treg also differ from Treg of lymphoid organs at the molecular level, with the TF BACH2 repressing expression of tissue-specific genes (13) whereas the TF BATF induced expression of these genes (14) . One can immediately realize that providing a common definition of Treg across this diversity of phenotype and function represents a difficult challenge. Furthermore, Treg specific markers should ideally mark Treg only or should be minimally expressed by other cells of the immune system or other non-immune cells. This has been an overlooked issue since most of the so-called "Treg signatures" are established relative to CD4 + T conventional cells (Tconv), and not looking outside of Tconv (not mentioning major phenotypic differences used to define Treg and Tconv). Safety and efficacy of Treg-based therapies will surely benefit from targeting molecules and/or pathways truly specific to Treg.
In an attempt to resolve some of these issues, we reasoned that digging out a Treg meta-signature (TMS) from available datasets comparing well-defined Treg and Tconv should lead to a more robust signature than studies taken separately. As a starting point, we decided to focus our investigation in Mus Musculus, because many databases and tools are available in mice. We also focused our analysis on resting Treg freshly isolated ex vivo, taken from non inflammatory lymphoid organs, to avoid bias due to T cell activation and/or tissue localization.
This naive approach led to the first description of a "universal" Treg signature, which includes several known Treg specific markers but also new ones, such as the pro-enkephalin gene Penk, indicating a function for the endogenous opioid pathway in immunoregulation.
Methods

Extraction of Treg meta-signatures
The datasets used were selected based on a "Treg* AND (Tconv* OR Teff*) AND Mus Musculus" search in the GEO dataset web site (https://www.ncbi.nlm.nih.gov/gds). GEO datasets were manually inspected for inclusion of studies comparing fresh Treg with fresh Tconv from lymphoid organs. Only GSE17580 (15), GSE24210 (16), GSE37532 (17, 18) , GSE40685 (19) , GSE42021 (20) , GSE7852 (21), GSE50096 (22) , and GSE15907 (ImmGen Project (23)) were selected and a list of genes significantly up regulated in Treg compared to Tconv was determined for each dataset using GEO2R with an adjusted p.value cutoff of 0.05 (False Discovery Rate). The commonality within gene sets was determined using the online tool from the Bioinformatics Evolutionary Genomics department form the Ghent University (http://bioinformatics.psb.ugent.be/webtools/Venn/). The Treg signature from Immuno Navigator (https://genomics.virus.kyoto-u.ac.jp/immuno-navigator/?) was generated by extracting 634 CD4 T cell samples and 240 Treg samples from the database. Differential gene expression was determined using Qlucore v3.4 with optimal variance set at 0.5 and False Discovery Rate <0.05. All but one dataset (GSE37532) where the Affymetrix Mouse Gene 1.0 ST Array was used, were generated using the Affymetrix Mouse Genome 430 2.0 Array.
Analysis of the TMS
All network analysis and visual representations were performed with Cytoscape v3.7 (24) (https://cytoscape.org). For enrichment analysis, we used ClueGO v2.5.5 and CluePedia 1.5.5 that integrates several ontology and pathway databases and creates a functionally organized network of GO/pathway terms (25, 26) . To represent PPI networks, we used the GeneMania (27) or STRING (28) Cytoscape applications, with embedded enrichment analysis. Expression of Penk in various tissues is represented by the graphical tool embedded in GEO2R, the Jamovi software (29) or Prism v8.3 (Graphpad). Putative regulators of Penk mRNA in mice was generated with Ingenuity Pathway Analysis (Qiagen)
Mice
All mice were on a C57Bl/6J background. Foxp3-IRES-GFP (Foxp3-GFP) knock-in mice were kindly given by Dr Bernard Malissen (CIML, Marseille). Mice were housed under specific pathogen-free conditions. All experimental protocols were approved by the local ethics committee and are in compliance with European Union guidelines.
Mass Cytometry
For labelling of antibodies, Maxpar Antibody Labeling Kit (Fluidigm) was used according to the manufacturer instructions. Briefly, lanthanide was loaded with metal and antibody was reduced, in parallel, using TCEP solution (Thermo Scientific). Then, loaded lanthanide was added to reduced antibody before incubation for 90min at 37°C, Finally, the metal-conjugated antibody was diluted in 100uL in Antibody Stabilizer (CANDOR® Bioscience). Up to 5. 
Tissue preparation and cell sorting
For CNS analysis, the spinal cord and the brain were harvested from mice. CNS samples were digested in type IV collagenase (1 mg/ml) and DNase I (100 µg/ml) for 30 min at 37°C.
Tumors and peripheral lymphoid organs were digested with 0.84mg/mL of collagenase IV and 10μg/mL DNAse I (Sigma Aldrich) for 40min at 37°C with an intermediate flushing of the tissue. To eliminate dead cells and debris, cell suspensions were isolated on a Percoll gradient (40/80). Rings were collected, washed, and cell pellets were resuspended in PBS 3% SVF before counting. Tregs were purified after enrichment of CD25+ cells using biotinylated anti-CD25 mAb (7D4) and anti-biotin microbeads (Miltenyi Biotec), followed by CD4 staining (RM4.5) and cell sorting using the BD FACSAria II. Tconvs were purified after enrichment of CD25-cells using biotinylated anti-CD25 mAb (7D4) or of CD8-CD19-CD11b-cells using biotinylated anti-CD8 (53-6.7), CD19 (1D3) and CD11b (M1/70) mAbs and antibiotin microbeads (Miltenyi Biotec), followed by CD4 staining (RM4.5) and cell sorting using the BD FACSAria II.
TNFR agonists in vitro stimulation
The protocol has been described in details elsewhere (30) . Briefly, purified Treg were sorted from Foxp3-GFP mice and 1,5.10 5 cells were cultured in 96-flat-well plates with anti-CD3/anti-CD28 (both coated at 2mg/ml) and IL-2 (10ng/ml). The following soluble TNFRSF agonists were used to co-stimulate Tregs: anti-4-1BB mAb (10 µg/ml, 3H3, BioXcell), OX40L (100 ng/ ml, AdipoGen), and the TNFR2 agonist TNC-sc(mu)TNF80 (STAR2) (12 ng/ml).
RNA-Seq analysis
RNA was extracted from sorted cells using the NucleoSpin RNA XS kit from Macherey-Nagel, quantified using a ND-1000 NanoDrop spectrophotometer (NanoDrop Technologies) and purity/integrity was assessed using disposable RNA chips (Agilent High Sensitivity RNA ScreenTape) and an Agilent 2200 Tapestation (Agilent Technologies, Waldbrunn, Germany). Absolute counts per million reads (CPM) were retrieved to quantify Penk transcript abundance in our experimental datasets.
Results
Analysis of the GEO Treg meta-signature
As a starting point, we searched for a common Treg signature (that is a list of genes differentially expressed in Treg compared to conventional T cells (Tconv)) across publicly available datasets retrieved from the GEO web site. We manually selected 8 datasets based on subjective criteria explicited below, and availability of the GEO2R analytical tool for the dataset. We deliberately limited the search to cells isolated from peripheral lymphoid tissues at steady state. Among the 8 datasets, 4 had been generated from lymph node cells, 3 from spleens and 1 from the bone marrow, 7 had been generated in C57BL/6 and one in BALB/c mice. Various ages and sexes were present in the datasets (range: 6-36 weeks-old). Various Treg sorting strategies were also used, from classical CD25 + sorting to isolation of GFP + cells from Foxp3-GFP transgenic mice. So we believe that the 8 chosen datasets were representative of typical Treg profiles found in many studies. For each dataset, we generated a list of differentially expressed genes with a cutoff based on a false discovery rate inferior to 0.05 and a log2 fold change superior to 1. We then established a list of differentially expressed genes common to the 8 datasets: 58 genes were found to be common to all 8 datasets. To gain biological insights from this list of genes, we generated a network of putative protein-protein interactions (PPI), protein-DNA and genetic interactions, pathways, reactions, gene and protein expression data, protein domains and phenotypic screening profiles from the Treg meta-signature (TMS) using the Genemania Cytoscape application, linking nodes of the network based on a score aggregating experimental and literature-based interactions (27) ( Figure 1A) . We represent the mean fold-change as a color code and the numbers of neighbors connected to each node (degree) as the size of the node to highlight some noticeable facts: Foxp3 and Il2ra were the most differentially expressed genes and were also among the most connected genes to other members of the network, as expected from the sorting Treg strategy used to generate these datasets. The well described Treg marker Ctla-4 was also highly differentially expressed and connected to other members of the network. Only Tnfrsf4 (OX40) was more connected to the network but had a slightly lower fold change, much like Tnfrsfr9 (4-1BB) and Tnfrsf1b (TNFR2). Genes with high fold-change but lower degree were Itgae (CD103), Rgs1, Klrg1, Ikzf2 (HELIOS), Nrp1 and surprisingly Penk, a gene coding for the proenkephalin, precursor of Met-enkephalin, an important mediator of peripheral nociception (pain perception). This in silico isolation of many known Treg markers confirms the validity of our approach and suggest that novel molecules isolated by this method, such as Penk, could be considered as reliable Treg "markers".
To gain further biological insights from the TMS, we performed an enrichment analysis using the ClueGO plugin in Cytoscape which interrogates several ontology/pathways databases simultaneously and produce a network of ontologies/pathways terms according to the statistical significance of the enrichment (26) ( Figure 1B) . As expected, most of the significant GO/pathway terms revolved around T cell proliferation and its regulation. Among the TMS, only few genes belong to several pathways at the same time and Foxp3 was the most prominent one. Surprisingly, Slamf1 (CD150) and Prnp (CD230) were also connected to several related ontologies. Of note is that TNF-related ontologies were enriched given the presence of 3 members of the TNF Receptor Superfamily in the TMS.
Analysis of the Immuno-Navigator Treg meta-signature.
To confirm and extend the findings, we then turned to the Immuno-Navigator database, and Ctla4 being both highly differentially expressed and most connected to other members of the network. Of note is that Cpe, coding for Carboxypeptidase E, responsible with other convertases for processing proenkephalin into biologically active MENK peptides (33) , was present in this signature. To go further, we next investigated the overlap between the ImmunoNavigator signature and the TMS. There was a 50% overlap in genes differentially expressed in CD4 and Treg from the Immuno-Navigator database relative to our more stringent TMS ( Figure 2C) . A list of 31 common genes was then projected into a network of PPI to search for enrichment for some biological functions ( Figure 2D ). Most members of this list were expressed at the plasma membrane and were involved in signal transduction. Interestingly, the list contains well-known markers of Treg (Foxp3, Il2ra, Ctla4, etc) but also some unexpected genes, including Penk, Cst7, or CD83. Thus, we propose that this condensed network constitute a "core" set of genes that defines Treg, and that Penk is a reliable Treg marker.
Mass cytometry analysis of the TMS
We next sought to determine whether this "core" set of genes was really restricted to Treg at the protein level relative to other immune cell subsets beyond Tconv. For that, we established the expression profile of some markers of the TMS in various immune cell subsets with a 38-parameters mass cytometry panel in peripheral lymphoid organs and in a syngeneic tumor model (Table supplemental 1 
Penk expression by Treg in various tissues and inflammatory conditions
Following on the surprising observation that Penk was a highly specific Treg genetic marker, we wanted to confirm this observation at the protein level. Deceptively, PENK was not listed in 2 different databases reporting the proteomes of murine Treg and Tconv, preventing any differential expression analysis to be performed (34, 35) . Furthermore, a monoclonal antibody to murine PENK is currently not available, preventing direct detection by cytometry.
Then, we asked whether Penk mRNA over expression could be limited to peripheral lymphoid organs, since most of the data analyzed so far were generated in spleens or lymph nodes. A rapid survey of studies examining gene expression in Tconv and Treg in various tissues showed that Penk was found to be over expressed by Treg in the thymus (21) and in several tissues, including fat (17, 18) , and muscle (22) (Figure 4A ). We also independently verified over expression of Penk in Treg relative to Tconv in our own set of RNA-Seq data from lymph nodes of normal mice ( Figure 4B ). Finally, we investigated whether Penk mRNA could be modulated in Treg in various inflammatory conditions ( Figure 4C ). In the CNS of mice undergoing Experimental Autoimmune Encephalitis (EAE), we observed that Penk was down modulated compared to non-inflamed lymph nodes. In contrast, we observed massive up regulation of Penk mRNA in Treg of the tumor relative to the draining LN.
Analysis of the genes most correlated to Penk mRNA
In order to gain mechanistic insights into the regulation of Penk expression in Treg, we first established a network linking the genes most correlated to Penk mRNA from the ImmunoNavigator database in all cell types combined ( Figure 5A ). This network included several members of the TMS, including Foxp3, Ikzf4, Ncmap, Ctla-4, or Gpr83, showing that Penk was highly correlated with some genes of the TMS defined above. The high correlation between Foxp3 and Penk is illustrated in figure 5B , where the co expression of Foxp3 and Penk in Treg is also clearly visible. We next interrogated the Immuno-Navigator database to establish a network of the genes most correlated to Penk specifically in Treg ( Figure 5C ).
Penk was highly correlated to 4 TNFR members (Tnfrsf1b (TNFR2), Tnfrsf4 (OX40), Tnfrsf9 (4-1BB) and Tnfrsf18 (GITR)), and to the TF Batf (illustrated in figure 5D ), suggesting that Penk expression in Treg might be regulated by TNFR signaling and BATF.
Penk mRNA expression is regulated by TNFR signaling and BATF-AP-1
To investigate this possibility, we turned to our own set of data establishing in vitro the transcriptome of TNFR-stimulated Treg by RNA sequencing (30) . Indeed, Penk expression was increased relative to controls with TNFR2, OX40 and 4-1BB agonists and this was more marked at 36h post stimulation ( Figure 6A) . Furthermore, the expression of Batf was also increased by TNFR agonists relative to controls and at an earlier time point than Penk ( Figure   6B 
Discussion
To our knowledge, the present report is the first attempt to define a "universal" Treg signature in mice by a meta analysis of published and available datasets. Our TMS provide a more solid appreciation of Treg-specific genes relative to the Immuno-navigator database which includes many types of heterogeneous samples. Our unbiased approach confirms that the genes belonging to the interleukin-2 signaling pathway (Il2ra, Il2rb) and of the TNF receptor super-family (Tnfrsf4, Tnfrsf9) are central to their identity. Our gene ontology enrichment analysis of the TMS also confirms that the "core" set of genes belongs to biological processes important for Treg function; regulation of T cell proliferation and cytokine signaling pathway. Finally, the preferred cellular localization of the TMS gene products at the cell surface highlights the dependency of Treg to external stimulus for their function and to preserve their identity. This is a view supported by functional plasticity of Treg (effector class control), and possible acquisition of effector functions in some inflammatory conditions. One point of caution for the interpretation of PPI networks is that mRNA expression may or may not be correlated with protein expression, and thus with biological functions. For instance, a recent study has found strong discrepancies between mRNA and protein levels in human Treg (38) . This low correlation between mRNA and protein levels was also observed in human Treg induced in vitro (39) but surprisingly not in murine "natural" Treg (34) . Whether this is a true specie-specific difference or whether it is related to technical issues remains to be investigated. This is an important matter since it relates to the more general question of inferring biological insights from a list of differentially expressed genes. Collecting a proteomic Treg meta-signature from all available proteomic studies in mice, properly normalized and corrected for batch effect, will bring essential informations to that matter.
A few genes stand out to be highly enriched in Treg relative to other immune subsets at the protein level and some significant differences were noted when the periphery and the tumor were compared. Everything combined, we established that, relative to Foxp3 (47, 48) . However, mice deficient for PENK were also protected from EAE, in contradiction with a protective role for MENK in EAE (49) . These discrepancies might be explained by the fact that PENK is also expressed by cells of the CNS with unknown impact on the development of the disease. To 
